Patients with hepatocellular carcinoma and chronic hepatitis C may
experience antiviral and antitumoral benefits from treatment with
tremelimumab, according to results of a recent pilot study.
In the phase 2, noncontrolled, multicenter, open-label trial,
researchers administered 15 mg/kg tremelimumab intravenously daily to 21
adult patients with chronic HCV genotype 1b and hepatocellular carcinoma
(HCC) for 90 days for a maximum of four cycles or until severe toxicity
or tumor progression occurred. Toxicity was evaluable in 20
participants and tumor response was measurable in 17 cases.